KR20110095486A - A composition for anti-cholesterolemia or anti-obesity activity containing the polyphenol extracts from phellinus baumii - Google Patents
A composition for anti-cholesterolemia or anti-obesity activity containing the polyphenol extracts from phellinus baumii Download PDFInfo
- Publication number
- KR20110095486A KR20110095486A KR1020100014970A KR20100014970A KR20110095486A KR 20110095486 A KR20110095486 A KR 20110095486A KR 1020100014970 A KR1020100014970 A KR 1020100014970A KR 20100014970 A KR20100014970 A KR 20100014970A KR 20110095486 A KR20110095486 A KR 20110095486A
- Authority
- KR
- South Korea
- Prior art keywords
- baumi
- polyphenol extract
- fatty liver
- obesity
- hyperlipidemia
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 74
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 10
- 230000000694 effects Effects 0.000 title claims description 22
- 241001556385 Sanghuangporus baumii Species 0.000 title abstract description 10
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 37
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 37
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 37
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 37
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 37
- 208000008589 Obesity Diseases 0.000 claims abstract description 27
- 235000020824 obesity Nutrition 0.000 claims abstract description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 8
- KKEIHFGUYDHUBS-HNQUOIGGSA-N 3-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-8,9-dihydroxypyrano[4,3-c]isochromene-1,6-dione Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(OC1=O)=CC2=C1C1=CC(O)=C(O)C=C1C(=O)O2 KKEIHFGUYDHUBS-HNQUOIGGSA-N 0.000 claims abstract description 6
- ZGKUEJPXTILOCD-ILBGXUMGSA-N Inoscavin A Natural products CC1=CC(=O)[C@]2(O1)[C@H](OC3=C2C(=O)OC(=C3)C=Cc4ccc(O)c(O)c4)c5ccc(O)c(O)c5 ZGKUEJPXTILOCD-ILBGXUMGSA-N 0.000 claims abstract description 6
- SGJNQVTUYXCBKH-UHFFFAOYSA-N hispidin Natural products O1C(=O)C=C(O)C=C1C=CC1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-UHFFFAOYSA-N 0.000 claims abstract description 6
- KYFXISLAEBFZFO-UHFFFAOYSA-N Davallialactone Natural products O1C(C)=CC(=O)C(C=2C(OC(C=CC=3C=C(O)C(O)=CC=3)=CC=2O)=O)C1C1=CC=C(O)C(O)=C1 KYFXISLAEBFZFO-UHFFFAOYSA-N 0.000 claims abstract description 5
- CGMQDMKDINCGOB-UHFFFAOYSA-N hypholomine B Natural products O1C(=O)C=C(O)C=C1C1C(C(=O)OC(C=CC=2C=C(O)C(O)=CC=2)=C2)=C2OC1C1=CC=C(O)C(O)=C1 CGMQDMKDINCGOB-UHFFFAOYSA-N 0.000 claims abstract description 5
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 claims abstract description 4
- KKEIHFGUYDHUBS-UHFFFAOYSA-N phelligridin D Natural products C1=C(O)C(O)=CC=C1C=CC(OC1=O)=CC2=C1C1=CC(O)=C(O)C=C1C(=O)O2 KKEIHFGUYDHUBS-UHFFFAOYSA-N 0.000 claims abstract description 4
- CGMQDMKDINCGOB-NJYVMNEESA-N (2s,3s)-2-(3,4-dihydroxyphenyl)-6-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(4-hydroxy-6-oxopyran-2-yl)-2,3-dihydrofuro[3,2-c]pyran-4-one Chemical compound O1C(=O)C=C(O)C=C1[C@H]1C(C(=O)OC(\C=C\C=2C=C(O)C(O)=CC=2)=C2)=C2O[C@@H]1C1=CC=C(O)C(O)=C1 CGMQDMKDINCGOB-NJYVMNEESA-N 0.000 claims abstract description 3
- KYFXISLAEBFZFO-NJPHHMIOSA-N 6-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-[(2s,3r)-2-(3,4-dihydroxyphenyl)-6-methyl-4-oxo-2,3-dihydropyran-3-yl]-4-hydroxypyran-2-one Chemical compound C1([C@@H]2[C@H](C(=O)C=C(O2)C)C=2C(OC(\C=C\C=3C=C(O)C(O)=CC=3)=CC=2O)=O)=CC=C(O)C(O)=C1 KYFXISLAEBFZFO-NJPHHMIOSA-N 0.000 claims abstract description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 25
- VJLLDPFYQAJLKH-UHFFFAOYSA-N 3-(2-phenylethenyl)pyran-2-one Chemical compound O=C1OC=CC=C1C=CC1=CC=CC=C1 VJLLDPFYQAJLKH-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 241000604739 Phoebe Species 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- -1 Pb211 Chemical compound 0.000 abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 9
- 230000001629 suppression Effects 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract 2
- SDJYPLYGBCMOGL-RRAWIICHSA-N 6-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-[(1z,3z)-1-(3,4-dihydroxyphenyl)-3-hydroxy-5-oxohexa-1,3-dien-2-yl]-4-hydroxypyran-2-one Chemical compound OC=1C=C(\C=C\C=2C=C(O)C(O)=CC=2)OC(=O)C=1/C(/C(/O)=C/C(=O)C)=C/C1=CC=C(O)C(O)=C1 SDJYPLYGBCMOGL-RRAWIICHSA-N 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 26
- 235000009200 high fat diet Nutrition 0.000 description 24
- 150000002632 lipids Chemical class 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 18
- 210000005228 liver tissue Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 11
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 229940002552 xenical Drugs 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000016267 Leptin Human genes 0.000 description 6
- 108010092277 Leptin Proteins 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 6
- 229940039781 leptin Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 108010018763 Biotin carboxylase Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JZRMMLYGOBWIGY-UHFFFAOYSA-N baumin Natural products O1C(CC(=O)OC)=CC(=O)C(C=2C(OC(C=CC=3C=C(O)C(O)=CC=3)=CC=2O)=O)C1C1=CC=C(O)C(O)=C1 JZRMMLYGOBWIGY-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011629 hyperlipidemia animal model Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011623 obesity animal model Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 3
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- JZRMMLYGOBWIGY-HZFVGLMFSA-N methyl 2-[(2s,3r)-2-(3,4-dihydroxyphenyl)-3-[6-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxy-2-oxopyran-3-yl]-4-oxo-2,3-dihydropyran-6-yl]acetate Chemical compound C1([C@@H]2[C@H](C(=O)C=C(O2)CC(=O)OC)C=2C(OC(\C=C\C=3C=C(O)C(O)=CC=3)=CC=2O)=O)=CC=C(O)C(O)=C1 JZRMMLYGOBWIGY-HZFVGLMFSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 2
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021149 fatty food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 101000963440 Bacillus subtilis (strain 168) Biotin carboxylase 1 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035637 spectrum-4 Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 고지혈, 지방간 또는 비만 예방 및 치료용 조성물에 관한 것으로서, 더욱 상세하게는 항고지혈증 활성이 우수하여 고지혈과 관련된 동맥경화증이나 허혈성 심장질환의 치료 및 예방을 위한 식품조성물 또는 약학조성물로서 유용한 바우미 상황버섯 (Phellinus baumii) 추출물 및 이 추출물에서 분리된 스티릴파이론 (styrylpyrone)계열의 화합물을 유효성분으로 함유하는 고지혈, 지방간 또는 비만 예방 및 치료용 조성물에 관한 것이다.
The present invention relates to a composition for the prevention and treatment of hyperlipidemia, fatty liver or obesity, comprising a polyphenol extract derived from the Baumi situation mushroom as an active ingredient, and more particularly, it is excellent in antihyperlipidemic activity and atherosclerosis or ischemic heart Prevention of hyperlipidemia, fatty liver or obesity containing Phellinus baumii extract useful as a food composition or pharmaceutical composition for the treatment and prevention of diseases, and styrylpyrone-based compounds isolated from the extract as an active ingredient And to therapeutic compositions.
최근 발표된 우리나라 사람들의 주요 사망원인을 보면 당뇨병, 동맥경화로 인한 심장병(심근경색증), 유방암, 대장암으로 인한 사망이 크게 증가하여 질병 패턴도 선진국 양상으로 바뀌고 있음을 볼 수 있다. Recently, the major causes of death among Korean people are the death pattern due to diabetes, arteriosclerosis, heart disease (myocardial infarction), breast cancer, and colon cancer.
이런 변화는 생활수준이 향상되면서 비만 인구가 크게 증가하고 있는 추세와 무관하지 않다. This change is not related to the trend of increasing obesity as living standards improve.
우리나라 성인의 비만 인구는 20% 정도로 구미 선진국에 비해 우려할 수준은 아니지만, 외모 때문에 무리하게 살을 빼는 젊은 여성들이 많고 이에 편승하여 건강을 해칠 수도 있는 비과학적인 방법들이 전문가의 무관심 속에 성행하고 있어 국민 건강에 심각한 위협이 되고 있는 실정이다. The obesity population of Korean adults is 20%, which is not a level of concern compared to the developed countries in the West, but there are many young women who lose their weight due to their appearance, and unscientific methods that may damage their health by piggybacking are prevalent in the indifference of experts. It is a serious threat to health.
특히, 비만인구들 중 당뇨병, 심장병 등의 주요 위험인자로 알려진 복부 비만인구가 점차 늘고 있고, 어린이 비만 역시 급격히 증가하는 추세를 보이고 있어 비만은 앞으로 우리 국민들의 주요 건강 문제로 자리 잡을 가능성이 높다. In particular, the abdominal obesity population, which is known as a major risk factor such as diabetes and heart disease, is gradually increasing, and child obesity is also rapidly increasing, and obesity is likely to become a major health problem in the future.
비만의 원인 중 하나로 나타나는 고지혈증은 우리 몸의 혈액 중에 콜레스테롤과 중성지질 농도가 정상이상으로 증가되어 있는 상태를 나타내는 것으로서, 고혈압 및 흡연과 더불어 관상동맥질환의 3대 위험 인자로 알려져 있다.Hyperlipidemia, which is one of the causes of obesity, is a condition in which cholesterol and triglyceride levels in the blood of our body are increased above normal, and are known as three major risk factors for coronary artery disease along with hypertension and smoking.
고지혈증은 혈액검사에서 총 콜레스테롤이 240mg/dL 이상이거나, 중성지방이 200 mg/dL 이상일시 진단되는 질병으로써, 근래에 돌연사가 젊은 층에 빈발하면서 더욱더 큰 관심이 모아지고 있다.Hyperlipidemia is a disease that is diagnosed when the total cholesterol is 240 mg / dL or more or triglyceride or more is 200 mg / dL or more in blood tests.
특히 고혈압, 고지혈증과 같은 심혈관 질환이 돌연사의 주된 원인으로 지목 되고 있으며, 국민 건강보험공단에 따르면 최근 5년간 고지혈증 환자는 2배 이상 급증했다고 보고된 바 있다.In particular, cardiovascular diseases such as hypertension and hyperlipidemia are the main causes of sudden death, and according to the National Health Insurance Corporation, hyperlipidemia patients have reported a twofold increase in recent five years.
또한 남성보다 여성 환자가 많고, 나이가 많을수록 환자가 더 많은 것으로 나타났다. In addition, there were more female patients than males, and older patients had more patients.
한편, 간은 기름진 음식 또는 알콜의 과다섭취 및 B형 또는 C형 간염 바이러스의 간염에 의해 그 기능이 저하되고, 이 상태가 방치될 경우 간염, 간경변증 간암 등으로 진행된다. On the other hand, the liver is deteriorated due to excessive intake of fatty foods or alcohol and hepatitis B or hepatitis C virus, if left untreated, hepatitis, cirrhosis, liver cancer, and so on.
특히 음식을 통한 과다한 지방식의 섭취 및 과도한 알콜 섭취는 간 조직에 지질이 쌓이는 지방간을 유발하며, 이때 혈청속의 GOT(glutamate-oxaloactate transaminase), GPT(glutamate-pyruvate transaminase)가 증가하게 된다. In particular, excessive intake of fatty foods and excessive alcohol intake causes fatty liver to accumulate lipids in liver tissue. At this time, GOT (glutamate-oxaloactate transaminase) and GPT (glutamate-pyruvate transaminase) increase in serum.
민간에서는 이러한 고혈압 예방 및 치료를 위하여 식품 및 천연물 유래 기능성 건강식품에 대한 연구가 아래와 같이 활발히 이루어지고 있는 추세이다.In the private sector, research on functional health foods derived from foods and natural products is actively conducted for the prevention and treatment of hypertension as follows.
즉, 최근 고지혈증을 억제하는 활성을 나타내는 유용한 생약자원으로 연잎이 보고된 바 있으며, 강력한 항산보고작용으로 혈관 벽의 손상을 막아 동맥경화와 심근경색 및 고혈압 예방물질인 쿼세틴(quercetin)을 양파로부터 추출하는 방법에 관한 연구가 이루어지고 있기도 하다. In other words, lotus leaf has recently been reported as a useful herbal resource that suppresses hyperlipidemia, and its powerful anti-oxidant activity prevents damage to the walls of blood vessels and extracts quercetin, a substance that prevents arteriosclerosis, myocardial infarction and hypertension, from onions. There is also research on how to do this.
또한, 식용버섯의 약리효과에 대해서도 지금까지 여러 분야에서 발표되어 왔으며, 고령화 사회를 맞이하게 된 현대에 이르러 먹으면서 건강을 증진시킨다고 하는 일석이조인 버섯식이에 의하여 이룰 수 있는 역할이 크게 기대되고 있다. In addition, the pharmacological effects of edible mushrooms have been announced in various fields so far, and the role that can be achieved by the mushroom diet that promotes health while eating in the modern age of aging society is greatly expected.
수백만 년 동안 버섯은 바이러스와 박테리아 등의 침입자들을 막아내기 위해 체내에서 방어물질들을 생산하여, 체내의 독성물질을 해독시키면서 환경에 적응하여왔다. For millions of years, mushrooms have been adapted to the environment by producing defenses in the body to stop invaders such as viruses and bacteria.
지금까지 알려진 약용 버섯들로부터, 이들이 생산하는 2차 대사산물인 이른바 방어물질은 인류에게 수천년동안 안전하면서도 효과적인 의약품으로 알려져 왔다. From medicinal mushrooms known to date, their so-called defense products, secondary metabolites, have been known to humans for thousands of years as safe and effective medicines.
특히, 수 천 종에 이르는 버섯 균류들은 독특하며 다양한 화합물들을 생산하는 것으로 알려져 있어 신약개발을 위한 좋은 소재로 이용할 수 있을 것이다. In particular, thousands of mushroom fungi are known to produce unique and diverse compounds that could be used as a good material for new drug development.
하지만 아직까지 버섯으로부터의 천연물 연구는 다른 미생물에 비해 저조한 편이며 특히 식용버섯 외에 영지, 표고, 차가버섯 등 전통 약용버섯에 대한 정확한 성분 및 함량분석 및 이들이 나타내는 효능에 대해서는 아직 명확히 연구된 바가 없어, 버섯을 소재로 한 천연약물의 개발은 미비한 상태이다.
However, research on natural products from mushrooms is still lower than that of other microorganisms. In particular, there are no clear studies on the exact components and contents of traditional medicinal mushrooms such as Ganoderma lucidum, shiitake, and chaga, and their efficacy. The development of natural medicines based on mushrooms is incomplete.
본 발명은 상기의 문제를 해결하기 위하여, 항고지혈, 지방간억제, 항비만 활성을 나타내는 바우미 상황버섯 폴리페놀 추출물 및 이 추출물에 함유되어있는 스티릴파이론 (styrylpyrone)계열의 화합물을 유효성분으로 함유하는 고지혈, 지방간 또는 비만 예방 및 치료용 조성물을 제공하는데 그 목적이 있다.In order to solve the above problems, the present invention comprises an anti-hyperlipidemic, fatty liver inhibitory, anti-obesity activity of Baumi situation mushroom polyphenol extract and styrylpyrone-based compound contained in the extract as an active ingredient. The purpose is to provide a composition for preventing and treating hyperlipidemia, fatty liver or obesity.
본 발명의 고지혈, 지방간 또는 비만 예방 및 치료용 조성물은 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 함유하는 것이 특징이다.The composition for preventing and treating hyperlipidemia, fatty liver or obesity of the present invention is characterized by containing a polyphenol extract derived from Baumi situation mushroom as an active ingredient.
또한, 상기 바우미 상황버섯 유래의 폴리페놀 추출물에서 분리된 스티릴파이론(styrylpyrone)계열의 화합물을 유효성분으로 함유하는 것이 특징이다.In addition, it is characterized by containing a compound of the styrylpyrone series isolated from the polyphenol extract derived from the Baumi situation mushroom as an active ingredient.
상기 바우미 상황버섯 유래의 폴리페놀 추출물은 음건 및 세절한 바우미 상황버섯을 메탄올, 에탄올, 아세톤 중 선택된 1종으로 추출한 후, 감압건조 한 다음, 헥산을 첨가하여 분배 추출한 후, 물층에 다시 에틸아세테이트를 첨가하여 분배 추출하여 제조된 것이 특징이다.The polyphenol extract derived from the Baumi situation mushroom is extracted from dry and fine Baumi situation mushrooms with one selected from methanol, ethanol and acetone, and then dried under reduced pressure, and extracted by adding hexane. It is characterized in that it is prepared by the partition extraction by addition of acetate.
상기 바우미 상황버섯 유래의 폴리페놀 추출물은 식품 조성물 또는 약학조성물로 사용 가능하다.The polyphenol extract derived from the Baumi situation mushroom can be used as a food composition or a pharmaceutical composition.
본 발명에 의해, 바우미 상황버섯 유래의 폴리페놀 추출물을 유효성분으로 포함하는 조성물은 식품 조성물 또는 약학 조성물로 사용된다.According to the present invention, a composition comprising a polyphenol extract derived from Baumi situation mushroom as an active ingredient is used as a food composition or a pharmaceutical composition.
또한, 상기 추출물에 함유되어 있는 스티릴파이론 (styrylpyrone)계열의 화합물을 유효성분으로 포함하는 조성물도 고지혈증 및 동맥경화와 관련된 심혈관계 질환, 지방간, 비만의 치료 및 예방을 위한 식품 조성물 또는 약학 조성물로 사용 하기도 한다.In addition, the composition comprising a compound of the styrylpyrone series contained in the extract as an active ingredient is also a food composition or pharmaceutical composition for the treatment and prevention of cardiovascular diseases, fatty liver, obesity associated with hyperlipidemia and atherosclerosis Also used.
도 1은 바우미 상황버섯 (Phellinus baumii) 폴리페놀 추출물에 함유되어 있는 스티릴파이론 (styrylpyrone)계열의 7개 화합물의 화학식을 나타낸 도면.
도 2는 Interfungin A 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 3은 Baumin(=Pb211) 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 4는 Davallialactone 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 5는 Hispidin 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 6은 Hypholomine B 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 7은 Phelligridin D 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼
도 8은 Inoscavin A 화합물을 나타낸 도면.
a:수소핵자기공명스펙트럼 b: 탄소핵자기공명스펙트럼
도 9는 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 의한 체중변화 및 체중증가율을 나타낸 도면.
A: 체중변화 B: 체중증가율
도 10은 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 혈액 내 지질변화를 나타낸 도면.
A: 총 콜레스테롤(Total cholesterol)
B: 중성지방(triglyceride)
C: 인지질(Phospholipid)
D: 유도지질(Non-esterified fatty acid)
E: 고밀도 지방단백질(HDL,Hig density lipoprotein)-C(cholesterol)
F: 저밀도 지방단백질(LDL,low density lipoprotein)-C(cholesterol)
도 11은 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물(PB)의 투여에 따른 혈당, GOT 및 GPT 변화를 나타낸 도면.
A: 혈당(Glucose)
B: 지오티(GOT, glutamic oxalacetic transaminase)
C: 지피티(GPT, glutamic pyruvate transaminase)
도 12는 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물(PB)의 투여에 따른 혈중 인슐린 및 렙틴의 변화를 나타낸 도면.
A: 인슐린(Insulin)
B: 렙틴(Leptin)
도 13은 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 지방간 억제 소견을 나타낸 도면.
도 14는 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 간조직 내 지방함량을 나타낸 도면.
A: 총 지질함량(Total lipid)
B: 중성지방(triglyceride)
C: 총 콜레스테롤(Total cholesterol)
도 15는 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 간조직 내 지질대사 관련 효소 활성을 나타낸 도면.
A: 지방산 합성효소(FAS, fatty acid synthase)
B: 카르니틴 팔미토일 전이효소(CPT, carnitine palmitoyl transferase)
도 16은 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 간조직 내 지질대사 관련 효소 유전자 발현 분석결과를 나타낸 도면.
A: 지방산 합성효소(FAS, fatty acid synthase)
B: 아세틸-코에이 카르복시화효소(ACC 1, acetyl CoA carboxylase 1)
C: 중성지방 합성효소(DGAT 1, diacylglycerol acyltransferase 1)
D: 스테로일-코에이 탈포화효소(SCD 1, steroyl CoA desaturase 1)
도 17은 고지방식이를 섭취시킨 마우스에서 바우미 상황버섯 유래의 폴리페놀추출물 (PB)의 투여에 따른 corn 투여로 유도 중성지방의 흡수 억제 효능을 나타낸 도면.1 is Baumi situation mushroom ( Phellinus) baumii ) A diagram showing the chemical formula of seven compounds of the styrylpyrone series contained in a polyphenol extract.
2 shows an Interfungin A compound.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
3 shows a Baumin (= Pb211) compound.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
4 shows the Davallialactone compound.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
5 shows Hispidin compound.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
6 shows a Hypholomine B compound.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
7 shows a Phelligridin D compound.
a: hydrogen nuclear magnetic resonance spectrum
8 shows Inoscavin A compounds.
a: hydrogen nuclear magnetic resonance spectrum b: carbon nuclear magnetic resonance spectrum
9 is a diagram showing the weight change and weight gain rate by administration of the polyphenol extract (PB) derived from Baumi mushroom in mice fed high fat diet.
A: weight change B: weight gain rate
Figure 10 is a diagram showing the change in lipids in the blood following administration of the polyphenol extract (PB) derived from Baumi mushroom in mice fed high fat diet.
A: Total Cholesterol
B: triglyceride
C: Phospholipid
D: Non-esterified fatty acid
E: High density lipoprotein (HDL) -C (cholesterol)
F: low density lipoprotein (LDL) -C (cholesterol)
11 is a diagram showing changes in blood glucose, GOT and GPT according to administration of the polyphenol extract (PB) derived from Baumi mushroom in mice fed high fat diet.
A: Glucose
B: GOT (glutamic oxalacetic transaminase)
C: GPT (glutamic pyruvate transaminase)
12 is a view showing the change of insulin and leptin in the blood following administration of the polyphenol extract (PB) derived from Baumi mushroom in mice fed high fat diet.
A: Insulin
B: Leptin
FIG. 13 is a diagram showing fatty liver suppression according to administration of a polyphenol extract (PB) derived from Baumi mushroom in mice fed high fat diet. FIG.
Figure 14 is a diagram showing the fat content in liver tissue following administration of the polyphenol extract (PB) derived from Baumi situation mushroom in mice fed high fat diet.
A: total lipid
B: triglyceride
C: Total Cholesterol
15 is a diagram showing the activity of lipid metabolism related enzymes in liver tissues according to the administration of the polyphenol extract (PB) derived from Baumi situation mushroom in mice fed high fat diet.
A: fatty acid synthase (FAS)
B: carnitine palmitoyl transferase (CPT)
16 is a diagram showing the results of analysis of lipid metabolism-related enzyme gene expression in liver tissues according to administration of Baumi-Shellfish-derived polyphenol extract (PB) in mice fed high fat diet.
A: fatty acid synthase (FAS)
B: Acetyl CoA Carboxylase (
C: triglyceride synthase (
D: steroyl CoA desaturase 1 (SCD 1)
17 is a diagram showing the effect of inhibiting the absorption of induced triglycerides by corn administration according to the administration of the polyphenol extract (PB) derived from the Baumi situation mushroom in mice fed high fat diet.
본 발명의 발명자들은 천연물질을 이용하여 고지혈증 및 동맥경화와 관련된 심혈관계 질환, 지방간, 비만의 치료 및 예방을 위한 기능성 식품, 또는 식품첨가물, 또는 약학조성물을 개발하기 위해 여러 연구를 한 결과, 바우미 상황버섯(Phellinus baumii) 폴리페놀 추출물이 항고지혈증, 지방간억제, 항비만 효과를 나타내는 것을 확인하였다.The inventors of the present invention have conducted a number of studies to develop functional foods, food additives, or pharmaceutical compositions for the treatment and prevention of cardiovascular diseases, fatty liver, obesity associated with hyperlipidemia and arteriosclerosis using natural materials. Phellinus baumii It was confirmed that the polyphenol extract showed antihyperlipidemia, fatty liver inhibition, anti-obesity effect.
바우미 상황버섯(Phellinus baumii)은 일명 장수 상황버섯이라 일컫는 것으로써, 야생의 자연산 상황버섯의 일종으로서 단백 다당체를 가장 많이 함유하고 있으며 번식이 잘되지 않는 희귀한 담자균류의 다년생 버섯 중에 하나이다. Phellinus baumii , also known as long- lived situation mushroom, is one of wild wild situation mushrooms and contains one of the most protein-polysaccharides and is one of rare rare perennial mushrooms.
이러한 바우미 상황버섯(Phellinus Baumii)은 최근 인공재배가 가능하고 1~2년만 지나면 수확을 할 수 있어 많은 농가에서 재배를 하고 있는 추세로, 바우미 상황버섯에 0.10~0.16%의 베티글루칸 성분을 함유하고 있는 것으로 나타나 NK(Natural Killer)세포와 인체면역 활성화 효과가 있다고 보고된 바 있다. Phellinus Baumii has been grown in many farms since it can be artificially cultivated and harvested after a year or two. Baumi glucan can contain 0.10% to 0.16% of Betiglucan. It has been reported to contain NK (Natural Killer) cells and immune activation effects.
상기와 같은 효능들을 나타내는 바우미 상황버섯(Phellinus baumii)의 항고지혈증, 지방간억제, 항비만 효과를 나타내는 주요성분들을 확인한 결과, 스티릴파이론 (styrylpyrone)계열의 화합물들이 분리되었다.As a result of confirming the main components exhibiting the antihyperlipidemia, fatty liver control, anti-obesity effect of the Phellinus baumii mushrooms showing the above effects, the compounds of the styrylpyrone series were isolated.
상기 분리된 화합물들은 구조분석을 통하여 화학구조를 확인한 결과 스티릴파이론(styrylpyrone)계열의 화합물인 인터푸긴 A(Interfungin A), 바우민(Baumin=피비211(Pb211)), 다발리아액톤(Davallialactone), 히스피딘(Hispidin), 히폴로마인 B(Hypholomine B), 펠리그리딘 D(Phelligridin D), 이노스카빈 A(Inoscavin A) 등 총 7개의 화합물로 이루어져 있음을 확인하였다. The separated compounds were identified by chemical analysis through structural analysis. As a result, styrylpyrone-based compounds such as Interfugin A, Baumin (Baumin = Phoebe 211 (Pb211), and Davallialactone) were identified. It was confirmed that the compound consists of a total of seven compounds, such as Hispidin (Hispidin), Hypholomine B (Pyelligridin D), Inoscavin A.
특히, 상기 7개의 화합물들은 바우미 상황버섯(Phellinus baumii) 에서는 처음으로 분리된 화합물이었다. In particular, the seven compounds were the first to be isolated from Phellinus baumii .
따라서, 본 발명에서는 바우미 상황버섯 폴리페놀 추출물의 항고지혈증, 지방간억제, 항비만 효과 및 추출물에 함유되어있는 스티릴파이론(styrylpyrone)계열의 7개의 화합물을 지표물질로 하여 본 발명을 완성하게 되었다.
Therefore, in the present invention, the antihyperlipidemia, fatty liver suppression, anti-obesity effect and the styrylpyrone family of compounds contained in the extract of Baumi Situary mushroom polyphenol extract were completed as an indicator. .
이하, 본 발명인 고지혈, 지방간 또는 비만 예방 및 치료용 조성물에 대해 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail for the composition for preventing and treating hyperlipidemia, fatty liver or obesity.
본 발명이 특징으로 하는 바우미 상황버섯 폴리페놀 추출물과 이 추출물로부터 활성물질을 분리하기 위해서는 바우미 상황버섯을 알콜류, 아세테이트류, 에테르류, 아세톤류, 탄화수소류 등 중에서 선택된 유기용매에 의하여 추출, 물의 분배, 컬럼 크로마토그라피 등 버섯성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합하여 용이하게 얻을 수 있다. In order to separate the Baumi situation mushroom polyphenol extract and the active substance from the extract, the Baumi situation mushroom is extracted with an organic solvent selected from alcohols, acetates, ethers, acetones, hydrocarbons, and the like. A well-known method used for separation extraction of mushroom components, such as water distribution and column chromatography, can be easily obtained by combining individually or suitably.
이때, 바우미 상황버섯을 그대로 사용하거나 또는, 버섯자실체 및 균사체 배양액을 사용하여 추출하기도 하며, 조 추출물은 필요에 따라서 상법에 따라서 더욱 정제하여 사용할 수도 있다. At this time, the Baumi situation mushroom may be used as it is, or may be extracted using a mushroom fruiting body and mycelium culture medium, and crude extract may be further purified according to the conventional method as needed.
본 발명에 따른 바우미 상황버섯 폴리페놀 추출물과 이 추출물에 함유되어있는 스티릴파이론(styrylpyrone)계열의 7개의 화합물을 효율적으로 분리할 수 있는 바람직한 방법은 다음과 같다. Baumi situation mushroom polyphenol extract according to the present invention and a preferred method for efficiently separating the seven compounds of the styrylpyrone series contained in the extract is as follows.
1) 바우미 상황버섯 추출물을 탄소수 1 내지 6의 지방족 알콜 및 탄소수 1 내지 10의 지방족 탄화수소 중에서 선택된 용매로 추출하는 과정 -> 2) 상기 용매 추출물을 헥산 및 에틸아세테이트 용매를 사용하여 분배 추출하여 폴리페놀 분획을 획득하는 과정-> 3) 상기 폴리페놀 추출액을 클로로포름-메탄올 용리액을 사용하여 실리카젤 컬럼 크로마토그래피하는 과정-> 4) 상기 용출액을 메탄올을 사용하여 세파덱스 LH-20 컬럼 크로마토그래피하는 과정; 또는 상기 용출액을 40 ~60 % 메탄올을 사용하여 분취용 고속 액체 크로마토그래피(preparative HPLC)를 실시하여 화합물을 각각 분리 수득하는 과정으로 이루어진다.
1) A process for extracting Baumi situation mushroom extract with a solvent selected from aliphatic alcohols having 1 to 6 carbon atoms and aliphatic hydrocarbons having 1 to 10 carbon atoms-> 2) The solvent extract is extracted by using hexane and ethyl acetate Process of obtaining a phenol fraction-> 3) Process of silica gel column chromatography of the polyphenol extract using chloroform-methanol eluent-> 4) Process of Sepadex LH-20 column chromatography of the eluent using methanol ; Alternatively, the eluate is subjected to a preparative high performance liquid chromatography (preparative HPLC) using 40 to 60% methanol to separately obtain the compounds.
상기의 방법으로 얻어진 바우미 상황버섯 유래의 폴리페놀추출물의 고지방식이로 유도한 고지혈증 및 비만 동물모델에서 체증증가, 혈중 총 콜레스테롤(total cholesterol)과 트리글리세라이드(triglyceride)의 농도, 혈중 레핀(lepin) 농도, 지방간, 간조직 내 총 지질, 중성지방 및 콜레스테롤 함량 등을 측정한 결과, 전반적으로 대조군보다 PB를 투여한 군에서 현저하게 낮아진 것을 확인할 수 있었다. Increased body weight, total cholesterol and triglyceride concentrations, lepin in blood in hyperlipidemia and obese animal models derived from high-fat dietary polyphenolic extract derived from Baumi militia mushroom obtained by the above method ), Concentrations, fatty liver, total lipids, triglycerides and cholesterol content in liver tissues were significantly lower in the PB group than the control group.
또한, 비만 마우스의 간조직 내 지방산합성 효소인 FAS 활성이 억제 되었고, 지질 합성 관련 효소의 발현 증가는 바우미 상황버섯 유래의 폴리페놀추출물의 투여에 의하여 억제되었으며, 특히 FAS의 발현은 대조군보다 현저하게 감소된 것을 확인하였다. In addition, FAS activity, a fatty acid synthase in liver tissues of obese mice was inhibited, and the expression of lipid-synthesizing enzymes was suppressed by administration of polyphenol extracts derived from Baumi situation mushrooms. It was confirmed that the reduction.
이상과 같이, 본 발명의 바우미 상황버섯 유래의 폴리페놀추출물은 중성지질의 흡수를 억제하는 것으로 나타나 고지혈증 및 동맥경화와 관련된 심혈관계 질환, 지방간, 비만의 치료 및 예방을 위한 식품 조성물 또는 약학 조성물로 매우 유용하게 이용될 수 있다. As described above, the polyphenol extract derived from the Baumi situation mushroom of the present invention has been shown to inhibit the absorption of neutral lipids, and as a food composition or pharmaceutical composition for the treatment and prevention of cardiovascular diseases, fatty liver and obesity associated with hyperlipidemia and atherosclerosis It can be very useful.
또한, 본 발명의 바우미 상황버섯 유래의 폴리페놀 추출물에 함유되어있는 스티릴파이론(styrylpyrone)계열의 7개의 화합물을 유효성분으로 포함하는 조성물도 식품 조성물 또는 약학 조성물로 매우 유용하게 이용될 수 있다.In addition, a composition comprising seven compounds of the styrylpyrone family contained in the polyphenol extract derived from the Baumi situation mushroom of the present invention as an active ingredient may be very useful as a food composition or a pharmaceutical composition. .
특히, 본 발명의 바우미 상황버섯 유래의 폴리페놀 추출물 및 이 추출물에 분리된 스티릴파이론(styrylpyrone) 화합물은 고지혈, 지방간 또는 비만 예방 및 치료용 조성물의 유효성분으로 함유될 시, 조성물 전체중량 대비 0.0001 ~ 10.0 중량 %로 함유되며, 바람직하게는 0.1 ~ 10.0 중량 % 함유되는 것을 특징으로 한다.In particular, the polyphenol extract and the styrylpyrone compound isolated from the Baumi situation mushroom of the present invention when contained as an active ingredient of the composition for preventing and treating hyperlipidemia, fatty liver or obesity, compared to the total weight of the composition It is contained in 0.0001 to 10.0% by weight, preferably 0.1 to 10.0% by weight.
상기 유효성분의 함량이 0.0001 중량% 미만인 경우에는 항고지혈증, 지방간억제, 항비만 효과가 거의 나타나지 않으며, 10 중량 % 이상인 경우에는 함유량 증가에 대한 효과 증대 정도가 미미하면서, 제형상의 안정 및 안정성에 문제가 있으며 경제적이지도 못하다.When the content of the active ingredient is less than 0.0001% by weight, anti-hyperlipidemia, fatty liver suppression, anti-obesity effect is hardly exhibited, and when the content is more than 10% by weight, the effect of increasing the content is insignificant. There is a problem and it is not economical.
또한, 본 발명의 바우미 상황버섯 유래의 폴리페놀 추출물 및 이 추출물에 분리된 스티릴파이론(styrylpyrone) 화합물을 약학적 조성물로 이용할 시, 약제학적 분야에서의 공지의 방법에 의해 제조될 수 있고, 그 자체 또는 약학적으로 허용되는 담체, 부형제, 희석제 등과 혼합하여 분말, 과립, 정제, 캡슐제 또는 주사제 등의 제형으로 제조되어 사용될 수 있고, 이들은 경구 또는 비경구로 투여될 수 있다.In addition, when the polyphenol extract derived from the Baumi situation mushroom of the present invention and the styrylpyrone compound isolated on the extract as a pharmaceutical composition, it can be prepared by a known method in the pharmaceutical field, It may be prepared and used in the form of powders, granules, tablets, capsules or injections, etc., by themselves or in admixture with pharmaceutically acceptable carriers, excipients, diluents and the like, which may be administered orally or parenterally.
또한, 상기 약학 조성물을 투여하기 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. In addition, in addition to the active ingredient described above for administering the pharmaceutical composition may be prepared by including one or more pharmaceutically acceptable carriers.
약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added.
또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
본 발명의 조성물은 목적하는 방법에 따라 비경구 투여(예를 들어 정맥 내, 피하, 복강 내 또는 국소에 적용)하거나 경구 투여할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. The compositions of the present invention may be administered parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) or orally, depending on the desired method, and the dosage may be based on the weight, age, sex, health status, The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease.
본 발명에 따른 약학 조성물의 유효 투여량은 체내에서 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도 등에 따라 적절히 선택될 수 있으며, 하루 일회 내지 수회에 나누어 투여하는 것이 더욱 바람직하다.
The effective dosage of the pharmaceutical composition according to the present invention may be appropriately selected depending on the absorption rate, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, the severity of the disease to be treated, and once to several times a day. It is more preferable to administer separately.
이하, 본 발명에 대하여 실시예 및 실험예를 통하여 보다 상세히 설명하나, 이들이 본 발명의 범위를 제한하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but these do not limit the scope of the present invention.
<실시예 1> 바우미 상황버섯 유래의 폴리페놀 추출물의 제조Example 1 Preparation of Polyphenol Extract from Baumi Situary Mushroom
음건, 세절한 바우미 상황버섯 자실체 3 kg을 메탄올에 1 일 동안 침지하여 실온에서 추출한 후 감압 건조하여 용매를 제거하였다. 3 kg of dried and shredded Baumi situation mushroom fruiting bodies were immersed in methanol for 1 day, extracted at room temperature, and dried under reduced pressure to remove the solvent.
용매가 제거된 추출물에 동량의 헥산을 첨가하여 분배 추출한 후, 물층에 다시 에틸아세테이트를 첨가하여 분배 추출하고 용매층을 회수하여 폴리페놀이 함유된 추출물 얻었다.
The same amount of hexane was added to the extract from which the solvent was removed, followed by partition extraction. Then, ethyl acetate was added to the aqueous layer to perform partition extraction. The solvent layer was recovered to obtain an extract containing polyphenol.
<실시예 2> 바우미 상황버섯 유래의 폴리페놀 추출물로부터 스티릴파이론 (styrylpyrone)계열 화합물의 분리 및 정제Example 2 Isolation and Purification of Styrylpyrone Compounds from Polyphenol Extracts from Baumi Situary Mushrooms
농축한 폴리페놀 추출물을 헥산-에틸 아세테이트(50:1 ~1:1, v/v), 클로로포름-메탄올 (2:1)의 용매계를 사용하여 실리카겔 후레쉬 컬럼 크로마토그래피를 실시하고, 메탄올의 용매로 세파덱스 LH-20 컬럼 크로마토그래피를 실시하였다.The concentrated polyphenol extract was subjected to silica gel fresh column chromatography using a solvent system of hexane-ethyl acetate (50: 1 to 1: 1, v / v) and chloroform-methanol (2: 1), and a solvent of methanol. Sephadex LH-20 column chromatography was performed.
그 후 50 ~ 90%의 용매를 이용하여 solid phase extraction을 실시한 후 다시 70%의 메탄올을 이용하여 세파덱스 LH-20 컬럼 크로마토그래피를 실시하였다.Thereafter, solid phase extraction was performed using 50 to 90% of solvent, followed by Sephadex LH-20 column chromatography using 70% of methanol.
그 결과, 아래와 같은 7개의 화합물이 확인되었다(도 1).As a result, the following seven compounds were confirmed (FIG. 1).
1) Interfungin A 화합물(도 1a의 화학구조) 1) Interfungin A compound (chemical structure of FIG. 1A)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 464B) Molecular weight: 464
다) 분자식 : C25H20O9 C) Molecular formula: C 25 H 20 O 9
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)-도 2aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500 MHz, CD 3 OD)-Fig. 2a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)-도 2b
E) Carbon nuclear magnetic resonance spectrum: ppm (100MHz, CD 3 OD)-Fig. 2b
2) Baumin화합물(도 1b의 화학구조) 2) Baumin compound (chemical structure of Figure 1b)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 522B) Molecular weight: 522
다) 분자식 : C27H22O11 C) Molecular formula: C 27 H 22 O 11
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 3aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500 MHz, CD 3 OD)-Figure 3a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)- 도 3b
E) Carbon nuclear magnetic resonance spectrum: ppm (100MHz, CD 3 OD)-Fig. 3b
3) Davallialactone 화합물(도 1c의 화학구조) 3) Davallialactone compound (chemical structure of Figure 1c)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 464B) Molecular weight: 464
다) 분자식 : C25H20O9 C) Molecular formula: C 25 H 20 O 9
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 4aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500 MHz, CD 3 OD)-Figure 4a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)- 도 4b
E) Carbon Nuclear Magnetic Resonance Spectrum: ppm (100MHz, CD 3 OD)-Fig. 4b
4) Hispidin 화합물(도 1d의 화학구조) 4) Hispidin compound (chemical structure of Figure 1d)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 246B) Molecular weight: 246
다) 분자식 : C13H10O5 C) Molecular formula: C 13 H 10 O 5
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 5aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500 MHz, CD 3 OD)-Figure 5a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)- 도 5b
E) Carbon nuclear magnetic resonance spectrum: ppm (100MHz, CD 3 OD)-Fig. 5b
5) Hypholomine B 화합물(도 1e의 화학구조)5) Hypholomine B Compound (Chemical Structure of Fig. 1E)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 490B) Molecular weight: 490
다) 분자식 : C26H18O10 C) Molecular formula: C 26 H 18 O 10
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 6aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500MHz, CD 3 OD)-Fig. 6a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)- 도 6b
E) Carbon nuclear magnetic resonance spectrum: ppm (100MHz, CD 3 OD)-Fig. 6b
6) Phelligridin D 화합물(도 1f의 화학구조) 6) Phelligridin D compound (chemical structure of FIG. 1F)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 380B) Molecular weight: 380
다) 분자식 : C20H12O8 C) Molecular formula: C 20 H 12 O 8
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 7
D) Hydrogen nuclear magnetic resonance spectrum: ppm (500MHz, CD 3 OD)-Fig. 7
7) Inoscavin A 화합물(도 1g의 화학구조) 7) Inoscavin A Compound (Chemical Structure of Fig. 1G)
가) 성상 : 황색의 분말A) Appearance: Yellow powder
나) 분자량 : 462B) Molecular weight: 462
다) 분자식 : C25H18O9 C) Molecular formula: C 25 H 18 O 9
라) 수소핵자기공명스펙트럼 : ppm (500MHz, CD3OD)- 도 8aD) Hydrogen nuclear magnetic resonance spectrum: ppm (500MHz, CD 3 OD)-Figure 8a
마) 탄소핵자기공명스펙트럼 : ppm (100MHz, CD3OD)- 도 8b
E) Carbon nuclear magnetic resonance spectrum: ppm (100MHz, CD 3 OD)-Fig. 8b
<실시예 3> 바우미 상황버섯 폴리페놀 추출물이 함유된 식품첨가제의 제조Example 3 Preparation of a Food Additive Containing Baumi Situary Mushroom Polyphenol Extract
본 발명의 실시예 1의 방법에 의해 제조된 바우미 상황버섯 폴리페놀 추출물을 감압 농축 후 동결건조하여 분말로 제조하였다.Baumi situation mushroom polyphenol extract prepared by the method of Example 1 of the present invention was concentrated under reduced pressure and lyophilized to prepare a powder.
통상적인 식품 제조시 상기의 분말을 2 중량% 첨가하여 사용하였다.
2 wt% of the above powder was used to prepare a conventional food.
<실시예 4> 바우미 상황버섯 유래의 폴리페놀 추출물을 이용한 산제 제조Example 4 Preparation of Powder Using Polyphenol Extract from Baumi Situary Mushroom
실시예 1의 바우미 상황버섯 유래의 폴리페놀 추출물 2g2 g of polyphenol extract derived from Baumi mushrooms of Example 1
유당 1g1g lactose
상기의 성분을 혼합하고 기밀포에 충전하여 산제를 제조하였다.
The above ingredients were mixed and filled in airtight cloth to prepare a powder.
<실시예 5> 바우미 상황버섯 유래의 폴리페놀 추출물을 이용한 정제 제조Example 5 Preparation of Tablets Using Polyphenol Extracts from Baumi Situary Mushrooms
실시예 1의 바우미 상황버섯 유래의 폴리페놀 추출물 100㎎100 mg of polyphenol extract derived from Baumi mushrooms of Example 1
옥수수전분 100㎎Corn Starch 100mg
유 당 100㎎Lactose 100mg
스테아린산 마그네슘 2㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<실시예 6> 바우미 상황버섯 유래의 폴리페놀 추출물을 이용한 캡슐제 제조<Example 6> Preparation of capsules using the polyphenol extract derived from Baumi situation mushroom
실시예 1의 바우미 상황버섯 유래의 폴리페놀 추출물 100㎎100 mg of polyphenol extract derived from Baumi mushrooms of Example 1
옥수수전분 100㎎Corn Starch 100mg
유 당 100㎎Lactose 100mg
스테아린산 마그네슘 2㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
<실험예 1> 바우미 상황버섯 폴리페놀 추출물의 체중 및 지방중량변화 측정Experimental Example 1 Measurement of Body Weight and Fat Weight of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 바우미 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the Baumi situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 체중 및 지방중량변화를 측정하였다.Body weight and fat weight changes were measured to assay the hyperlipidemia, fatty liver and obesity related in vivo efficacy of the extract.
2) 실험방법2) Experiment Method
고지방식이로 유도한 고지혈증 및 비만 동물모델에서 실시예 1의 바우미 상황버섯 유래의 폴리페놀 추출물 PB 500 (500 ㎎/㎏)과 PB50 (50 ㎎/㎏) 투여군, 비교약제로서 지방흡수 억제제인 제니칼(xenical, 50 mg/kg)과 콜레스테롤 합성 저해제인 심바스타틴(simbastatin, 10 mg/kg)을 1일 1회 경구로 12주차까지 투여하면서 체중 및 지방중량 변화를 측정하였다.The polyphenol extract PB 500 (500 mg / kg) and PB50 (50 mg / kg) derived from the Baumi situation mushroom of Example 1 in the hyperlipidemia-induced hyperlipidemia and obesity animal model, which is a fat absorption inhibitor Xenical (50 mg / kg) and simvastatin (simbastatin, 10 mg / kg), a cholesterol synthesis inhibitor, were administered orally once a week until 12 weeks to determine body weight and fat weight changes.
3) 실험결과3) Experiment result
상기 실험결과, 도 9에 나타나있듯이 체중의 경우, 고지방식이를 섭취시킨 대조군과 비교하여, PB500을 투여한 실험군에서 8주차 까지는 고지방식이 대조군과 유사한 정도로 체중이 증가하다가, 9주 이후부터 차이를 보이기 시작하여 12주차에는 고지방식이 대조군이 41±0.9 g, PB500 및 PB50 투여군이 각각 38.1±1.2 g, 40.1±1.4 g으로 비슷한 체중을 유지하였으나, 체중 증가 비율을 계산한 결과, 고지방식이 대조군이 93.5±6.2%의 증가를 보인 반면 PB500 및 PB50 투여군에서는 78.2±7.5%, 83.4±4.9%의 증가를 각각 나타내어 체증증가가 억제되어진 것을 볼 수 있었다.
As a result of the experiment, as shown in Figure 9, compared to the control group ingested the high-fat diet, as compared to the control group fed the high-fat diet, the high-fat diet increased the weight to a similar level as the control group until the 8th week, the difference after 9 weeks At
<실험예 2> 바우미 상황버섯 폴리페놀 추출물의 혈액지질 분석Experimental Example 2 Blood Lipid Analysis of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 혈액지질을 분석하였다. Blood lipids were analyzed to assay the in vivo efficacy of hyperlipidemia, fatty liver and obesity of the extract.
2) 실험방법2) Experiment Method
고지방식이로 유도한 고지혈증 및 비만 동물모델에서 실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물 PB 500과 PB50 투여군, 비교약제로서 지방흡수 억제제인 xenical(50 mg/kg)과 콜레스테롤 합성 저해제인 simbastatin(10mg/kg)을 1일 1회 경구로 12주차까지 투여한 후 혈액을 채취하여 혈액 내 지질성분에 대한 분석을 시행하였다.In the high fat diet-induced hyperlipidemia and obesity animal model, the
3) 실험결과3) Experiment result
상기 실험결과, 도 10에 나타나 있듯이 대조군이 총 콜레스테롤(total cholesterol)의 경우 252.8±9.5 ㎎/㎗, 트리글리세리드(triglyceride)의 경우 72.7±3.3 ㎎/㎗를 나타낸 것과 비교하여 PB500과 PB50을 투여한 군에서는 total cholesterol이 242.5±12.7 ㎎/㎗, 246.7±3.0 ㎎/㎗였고 triglyceride이 74.8±3.3 ㎎/㎗, 65.5±2.2 ㎎/㎗를 각각 나타내었다. As a result, as shown in FIG. 10, the control group was administered PB500 and PB50 in comparison with 252.8 ± 9.5 mg / dl for total cholesterol and 72.7 ± 3.3 mg / dl for triglyceride. In total cholesterol, 242.5 ± 12.7 ㎎ / dl, 246.7 ± 3.0 ㎎ / dl, triglyceride was 74.8 ± 3.3 ㎎ / dl, 65.5 ± 2.2 ㎎ / dl, respectively.
NEFA (non-esterified fatty acid)의 경우 고지방식이 대조군을 제외하고 나머지 모든 군에서 유의하게 (Student's t-test, p<0.05) 증가함을 확인하였다.
In case of NEFA (non-esterified fatty acid), high fat diet increased significantly (Student's t- test, p <0.05 ) in all other groups except the control group.
<실험예 3> 바우미 상황버섯 폴리페놀 추출물의 혈당, GOT, GPT, insulin 및 leptin 분석Experimental Example 3 Analysis of Blood Sugar, GOT, GPT, Insulin and Leptin of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 혈당, GOT, GPT, insulin 및 leptin을 분석하였다. Blood glucose, GOT, GPT, insulin and leptin were analyzed to assay the hyperlipidemia, fatty liver and obesity related in vivo efficacy of the extract.
2) 실험방법2) Experiment Method
고지방식이로 유도한 고지혈증 및 비만 동물모델에서 실시예1의 바우미 상황버섯 유래의 폴리페놀추출물 PB 500과 PB50 투여군, 비교약제로서 지방흡수 억제제인 xenical (50 mg/kg)과 콜레스테롤 합성 저해제인 simbastatin (10mg/kg)을 1일 1회 경구로 12주차까지 투여한 후 혈액을 채취하여 혈당, GOT, GPT, insulin 및 leptin에 대한 분석을 시행하였다.In the high fat diet-induced hyperlipidemia and obesity animal model, the polyphenol extracts
3) 실험결과3) Experiment result
상기 실험결과, 도 11, 12에 나타나 있듯이, 혈당의 경우 고지방식이 대조군의 경우 289.5±8.2 ㎎/㎗을 나타낸 반면, PB500 투여군에서 258.0±7.4 ㎎/㎗을 나타내어 유의한 감소를 보였다 (Student's t-test, p<0.05).As shown in Figs. 11 and 12, the high-fat diet of blood glucose was 289.5 ± 8.2 mg / dL in the control group, while the PB500-administered group was 258.0 ± 7.4 mg / dL, which showed a significant decrease (Student's t -test, p <0.05 ).
한편, 고지방식이로 유도한 고지혈증 및 비만 마우스 모델에서 바우미 상황버섯 유래의 폴리페놀추출물 PB의 투여에 의한 혈중 insulin과 lepin 농도를 비교한 결과, 고지방식이 대조군의 insulin 농도가 3.2±0.5 ng/ml, PB500 투여군은 4.0±0.6 ng/ml, PB50 투여군은 2.7±0.2 ng/ml, xenical 투여군은 4.2±1.3 ng/ml 등을 나타내어 군 간에 큰 차이를 발견할 수 없었다. In the high fat diet-induced hyperlipidemia and obese mouse models, the plasma insulin and lepin concentrations of PB-derived phenolic PB extracts were compared to 3.2 ± 0.5 ng. / ml, PB500 group showed 4.0 ± 0.6 ng / ml, PB50 group showed 2.7 ± 0.2 ng / ml, xenical group showed 4.2 ± 1.3 ng / ml.
반면에, 혈중 leptin의 경우에는 고지방식이 대조군이 27.9±1.4 ng/ml, PB500 투여군은 21.1±2.7 ng/ml 및 PB50 투여군은 19.7±2.2 ng/ml, xenical 투여군은 22.2±3.3 ng/ml 등을 나타내어 PB 투여군의 leptin 농도가 대조군 보다 감소하였으며, 특히 PB50 투여군에서 의미있게 감소된 것으로 분석되었다 (Student's t-test, p<0.05).
On the other hand, in the case of leptin, 27.9 ± 1.4 ng / ml in the high-fat diet control group, 21.1 ± 2.7 ng / ml in the PB500 group, 19.7 ± 2.2 ng / ml in the PB50 group, and 22.2 ± 3.3 ng / ml in the xenical group. The leptin concentration in the PB-administered group was lower than that in the control group, especially in the PB50-administered group (Student's t- test, p <0.05).
<실험예 4> 바우미 상황버섯 폴리페놀 추출물의 병리조직학적 분석Experimental Example 4 Pathology of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 병리조직학적 분석을 하였다. Histopathological analysis was performed to assay the in vivo efficacy of the extract on hyperlipidemia, fatty liver and obesity.
2) 실험방법2) Experiment Method
고지방식이로 유도한 고지혈증 및 비만 동물모델에서 실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물 PB500과 PB50 투여군, 비교약제로서 지방흡수 억제제인 xenical (50 mg/kg)과 콜레스테롤 합성 저해제인 simbastatin (10mg/kg)을 투여한 동물의 간과 지방에 대한 병리조직학적인 관찰하였다.Polyphenolic extract PB500 and PB50 derived from the Baumi situation mushroom of Example 1 in the hyperlipidemia-induced hyperlipidemia and obesity animal model, xenical (50 mg / kg), a fat absorption inhibitor and simbastatin, a cholesterol synthesis inhibitor Histopathological observations of liver and fat of animals administered (10 mg / kg) were made.
3) 실험결과3) Experiment result
간조직의 경우에는 고지방식이 대조군의 경우 간조직 전반에 걸쳐 간세포 내 지방들이 침착되어 공포형태의 지방간 소견이 관찰되어 지방의 침착이 현저하게 높은 것을 알 수 있다. In the case of liver tissue, the fat diet was deposited in the hepatic cells throughout the liver tissue in the high fat diet control group, and the fear of fatty liver was observed.
이에 상기 실험결과, 도 13에 나타나 있듯이, PB500 투여군에서는 이와 같은 지방간 소견이 억제되어 있는 것을 볼 수 있었다.As a result, as shown in FIG. 13, it was found that such fatty liver findings were suppressed in the PB500-administered group.
지방간 소견에 대한 각 군의 형성 정도를 간의 중심정맥을 중심으로 하여 1:0~25%, 2 (26~50%), 3: 51~75% 및 4: 76~100% 등으로 나누어 semiquantitative하게 분석한 결과, 고지방식이 대조군이 4.0±0.0, xenical 투여군이 2.3±0.5, simbastatin 투여군이 3.4±0.4, PB500 및 PB50 투여군이 2.5±0.5, 3.2±0.3 등의 score로 나타나 바우미 상황버섯 유래의 폴리페놀추출물의 지방간 억제 효능을 관찰할 수 있었다.
The degree of formation of each group for fatty liver findings was semiquantitatively divided into 1: 0 ~ 25%, 2 (26 ~ 50%), 3: 51 ~ 75%, and 4: 76 ~ 100% centered on the central vein of the liver. As a result, high-fat diet control group scored 4.0 ± 0.0, xenical group 2.3 ± 0.5, simbastatin group 3.4 ± 0.4, PB500 and PB50 group 2.5 ± 0.5, 3.2 ± 0.3. Fatty liver inhibition effect of polyphenol extract was observed.
<실험예 5> 바우미 상황버섯 폴리페놀 추출물의 간조직내 지질함량 분석Experimental Example 5 Analysis of Lipid Content in Liver Tissues of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 간조직내 지질함량 분석을 하였다. Lipid content analysis was performed in the liver tissues to assay the hyperlipidemia, fatty liver and obesity-related in vivo efficacy of the extract.
2) 실험방법2) Experiment Method
고지방식이 유도 C57BL/6 비만 마우스에 실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물 (PB500, 500 mg/kg; PB100, 100 mg/kg) 투여군, 비교약제로서 xenical (20 mg/kg)을 1일 1회 경구로 12주차까지 투여한 후 간조직 내의 지방함량을 분석하였다.High-fat diet-induced polyphenol extract (PB500, 500 mg / kg; PB100, 100 mg / kg) derived from the Baumi situation mushroom of Example 1 in C57BL / 6 obese mice, xenical (20 mg / kg) as a comparative drug Was administered orally once a day until
3) 실험결과3) Experiment result
상기 실험결과, 도 14에 나타나 있듯이, 간 내 총 지질, 중성지방 및 콜레스테롤 함량이 대조군은 172.5±16.1 mg/g liver, 62.2±2.2 mg/g liver, 4.0±0.4 mg/g liver, PB500 군에서 108.9±10.4 mg/g liver, 39.2±5.8 mg/g liver, 3.1±0.2 mg/g liver, PB50 투여군에서 149.9±20.9 mg/g liver, 53.5±6.0 mg/g liver, 3.3±0.3 mg/g liver을 나타내어 간조직 내 총 지질, 중성지방및 콜레스테롤 함량이 대조군보다 PB를 투여한 군에서 낮아진 것을 확인할 수 있었다. As shown in FIG. 14, the total lipid, triglyceride and cholesterol contents in the liver were 172.5 ± 16.1 mg / g liver, 62.2 ± 2.2 mg / g liver, 4.0 ± 0.4 mg / g liver, and PB500 group. 108.9 ± 10.4 mg / g liver, 39.2 ± 5.8 mg / g liver, 3.1 ± 0.2 mg / g liver, 149.9 ± 20.9 mg / g liver, 53.5 ± 6.0 mg / g liver, 3.3 ± 0.3 mg / g liver in PB50 group It was confirmed that the total lipid, triglyceride and cholesterol contents in liver tissues were lower in the PB-administered group than the control group.
이러한 효과는 PB를 500 mg/kg로 투여한 PB500군에서 현저한 것을 알 수 있었다.This effect was remarkable in the PB500 group administered PB at 500 mg / kg.
Xenical 투여군의 경우 간 내 총 지질, 중성지방 및 콜레스테롤 함량이 115.6±38.8 mg/g liver, 41.0±3.1 mg/g liver, 2.9±0.1 mg/g liver로 PB500 투여군과 유사한 간 내 지방 침착을 보여주었다.
In the Xenical group, total lipid, triglyceride, and cholesterol contents in the liver were 115.6 ± 38.8 mg / g liver, 41.0 ± 3.1 mg / g liver, and 2.9 ± 0.1 mg / g liver, which showed similar intrahepatic fat deposition as the PB500 group. .
<실험예 6> 바우미 상황버섯 폴리페놀 추출물의 간조직 내 지질관련 대사 효소 활성 분석Experimental Example 6 Analysis of Lipid-Related Metabolic Enzyme Activity in Liver Tissues of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 간조직 내 지질관련 대사 효소 활성 분석을 하였다. Lipid-related metabolic enzyme activity in liver tissues was assayed for assaying the in vivo efficacy of hyperlipidemia, fatty liver and obesity of the extract.
2) 실험방법2) Experiment Method
실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물을 투여한 고지방식이 유도 C57BL/6 비만 마우스의 간조직 내 지방산합성 효소인 FAS와 지방산 에너지 대사를 촉진하는 것으로 CPT에 대한 활성을 분석하였다.The high-fat diet administered the polyphenol extract derived from the Baumi situation mushroom of Example 1 was analyzed to promote the fatty acid energy metabolism of FAS and fatty acid energy in liver tissues of C57BL / 6 obese mice.
3) 실험결과3) Experiment result
상기 실험결과, 도 15에 나타나 있듯이 대조군은 0.3±0.1 nmole/min/mg protein과 2.9±0.4 nmole/min/mg protein을 보인 반면, PB를 500 mg/kg의 농도로 투여한 PB500군에서는 0.1±0.01 nmole/min/mg protein과 2.9±0.3 nmole/min/mg protein, 50 mg/kg 농도로 투여한 PB50군에서는 0.1±0.2 nmole/min/mg protein과 3.1±0.2 nmole/min/mg protein를 각각 나타내어 대조군 보다 FAS 활성은 억제하는 것으로 나타났으나, CPT의 활성 상에는 영향을 미치지 않음을 알 수 있었다. Xenical을 투여한 군에서도 PB를 투여한 군과 비슷한 경향을 보였으나 PB의 투여보다는 그 정도가 약한 것으로 나타났다.
As shown in FIG. 15, the control group showed 0.3 ± 0.1 nmole / min / mg protein and 2.9 ± 0.4 nmole / min / mg protein, whereas PB500 group administered PB at a concentration of 500 mg / kg was 0.1 ±. In the PB50 group administered with 0.01 nmole / min / mg protein, 2.9 ± 0.3 nmole / min / mg protein, and 50 mg / kg concentration, 0.1 ± 0.2 nmole / min / mg protein and 3.1 ± 0.2 nmole / min / mg protein, respectively It was shown that the FAS activity was inhibited more than the control group, but it did not affect the activity phase of the CPT. Xenical group showed similar tendency to PB group but weaker than PB group.
<실험예 7> 바우미 상황버섯 폴리페놀 추출물의 간조직내 지질합성 관련 효소의 유전자 발현 분석Experimental Example 7 Analysis of Gene Expression of Lipid Synthesis-Related Enzyme in Liver Tissue of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 간조직내 지질합성 관련 효소의 유전자 발현 분석을 하였다. In order to assay the hyperlipidemia, fatty liver, and obesity-related in vivo efficacy of the extract, gene expression analysis of lipid-related enzymes in liver tissues was performed.
2) 실험방법2) Experiment Method
간 내 지질함량 및 지질 합성 효소의 활성을 측정한 결과, PB를 500 mg/kg의 농도로 투여한 군에서 항비만에 더 효과적인 결과를 얻어, 실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물을 500 mg/kg 농도로 투여한 비만 마우스에서 간조직 내 지질합성관련 효소의 발현을 분석하였다. As a result of measuring liver lipid content and lipid synthase activity, polyphenol extract derived from Baumi situation mushroom of Example 1 was obtained more effectively for anti-obesity in the group administered with PB at a concentration of 500 mg / kg. The expression of enzymes related to lipid synthesis in liver tissues was analyzed in obese mice administered at a concentration of 500 mg / kg.
3) 실험결과3) Experiment result
상기 실험결과, 도 16에 나타나 있듯이 고지방식이만 섭취시킨 대조군에서 acetyl CoA carboxylase 1 (ACC1)을 제외하고 fatty acid synthase (FAS), diacylglycerol acyltransferase 1 (DGAT1) 그리고 steroyl CoA desaturase 1 (SCD1)의 발현이 가장 높은 것으로 나타났다. As shown in FIG. 16, the expression of fatty acid synthase (FAS), diacylglycerol acyltransferase 1 (DGAT1) and steroyl CoA desaturase 1 (SCD1) except for acetyl CoA carboxylase 1 (ACC1) in the high-fat diet-only control group, as shown in FIG. 16. This was found to be the highest.
이러한 지질 합성 관련 효소의 발현 증가는 PB의 투여에 의하여 억제되었으며, 특히 FAS의 발현은 대조군보다 현저하게 감소된 것을 확인하였다.
The increased expression of these lipid synthesis enzymes was inhibited by the administration of PB, in particular, the expression of FAS was found to be significantly reduced than the control.
<실험예 8> 바우미 상황버섯 폴리페놀 추출물의 중성지방 흡수 저해 분석Experimental Example 8 Analysis of Inhibition of Neutral Fat Absorption of Baumi Situary Mushroom Polyphenol Extract
1) 재료준비1) Material Preparation
실시예 1의 상황버섯 유래의 폴리페놀 추출물을 준비하였다.The polyphenol extract derived from the situation mushroom of Example 1 was prepared.
상기 추출물의 고지혈증, 지방간 및 비만 관련 in vivo 효능을 검정하기 위해 중성지방 흡수 저해 분석을 하였다. Inhibition of triglyceride absorption in order to assay the hyperlipidemia, fatty liver and obesity related in vivo efficacy of the extract.
2) 실험방법2) Experiment Method
실시예 1의 바우미 상황버섯 유래의 폴리페놀추출물의 투여가 corn oil 유래 중성지방의 흡수 상에 미치는 영향을 평가하기 위하여, 대조군에는 vehicle만을, PB군에는 항비만에 더 효과적이었던 500 mg/kg 농도로 투여하였으며, 비교약제로 지질흡수 억제제인 xenical을 20 mg/kg 농도로 투여하고 corn oil 투여 30분, 60분 및 120분 후 각각 혈중 중성지질 농도를 측정하였다. In order to evaluate the effect of administration of the polyphenol extract derived from the Baumi situation mushroom of Example 1 on the absorption of corn oil-derived triglycerides, 500 mg / kg was more effective in vehicle only in the control group and anti-obesity in the PB group. Concentration was administered, 20 mg / kg concentration of xenical, a lipid absorption inhibitor as a comparative drug was measured 30 minutes, 60 minutes and 120 minutes after corn oil administration blood neutral lipid concentrations were measured.
3) 실험결과3) Experiment result
상기 실험결과, 도 17에 나타나 있듯이, Corn oil 투여 30분과 60분 후에 혈중 중성지질의 농도가 PB와 xenical의 투여에 의하여 감소되었으며, 120분 후에도 대조군의 혈중 중성지질 농도는 233.5±24.7 mg/dl 이었고, xenical과 PB500군에서 157.5±16.6 mg/dl,144.6±7.5 mg/dl로 각각 나타내어 대조군 보다 33%, 38% 정도 낮은 중성지질 농도를 보여주었다. As shown in FIG. 17, the concentration of triglyceride in the blood was reduced by the administration of PB and xenical after 30 and 60 minutes of corn oil administration, and the concentration of triglyceride in the control group was 233.5 ± 24.7 mg / dl after 120 minutes. , 157.5 ± 16.6 mg / dl and 144.6 ± 7.5 mg / dl in the xenical and PB500 groups, respectively, showing 33% and 38% lower triglyceride levels than the control group.
이러한 결과는 PB의 투여가 지질흡수 억제제인 xenical과 유사한 효과를 보여 중성지질의 흡수를 억제하는 것으로 사료된다.These results suggest that the administration of PB has a similar effect to that of xenical, a lipid absorption inhibitor.
Claims (6)
상기 바우미 상황버섯 유래의 폴리페놀 추출물은 음건 및 세절한 바우미 상황버섯을 메탄올, 에탄올, 아세톤 중 선택된 1종으로 추출한 후, 감압건조 한 다음, 헥산을 첨가하여 분배 추출한 후, 물층에 다시 에틸아세테이트를 첨가하여 분배 추출하여 제조된 것을 특징으로 하는,고지혈, 지방간 또는 비만 예방 및 치료용 조성물.The method of claim 1,
The polyphenol extract derived from the Baumi situation mushroom is extracted from dry and fine Baumi situation mushrooms with one selected from methanol, ethanol and acetone, and then dried under reduced pressure, and extracted by adding hexane. Dispersion extraction by the addition of acetate, characterized in that, hyperlipidemia, fatty liver or obesity prevention and treatment composition.
상기 바우미 상황버섯 유래의 폴리페놀 추출물에서 분리된 스티릴파이론(styrylpyrone)계열의 활성화합물을 유효성분으로 포함하는 것을 특징으로 하는,고지혈, 지방간 또는 비만 예방 및 치료용 조성물.The method of claim 1,
A styrylpyrone-based active compound isolated from the polyphenol extract derived from the Baumi situation mushroom, characterized in that it comprises an active ingredient, hyperlipidemia, fatty liver or obesity prevention and treatment composition.
상기 스티릴파이론(styrylpyrone)계열의 활성화합물은 인터푸긴 A(Interfungin A), 피비211(Pb211), 다발리아액톤(Davallialactone), 히스피딘(Hispidin), 히폴로마인 B(Hypholomine B), 펠리그리딘 D(Phelligridin D), 이노스카빈 A(Inoscavin A) 중 선택된 1종 내지 7종인 것으로, 항고지혈증, 지방간억제, 항비만 효과를 갖는 것을 특징으로 하는, 고지혈, 지방간 또는 비만 예방 및 치료용 조성물.The method of claim 3,
The active compounds of the styrylpyrone series include Interfugin A, Phoebe 211, Pb211, Davallialactone, Hispidin, Hypholomine B, and Feligry Dean D (Phelligridin D), Inoscavin A (Inoscavin A) selected from one to seven species, characterized in that having antihyperlipidemia, fatty liver inhibition, anti-obesity effect, hyperlipidemia, fatty liver or obesity prevention and treatment composition.
상기 바우미 상황버섯 유래의 폴리페놀 추출물을 포함하는 것을 특징으로 하는, 식품 조성물.The method of claim 1,
Food composition, characterized in that it comprises a polyphenol extract derived from the Baumi situation mushroom.
상기 바우미 상황버섯 유래의 폴리페놀 추출물을 포함하는 것을 특징으로 하는, 약학 조성물.The method of claim 1,
The pharmaceutical composition, characterized in that it comprises a polyphenol extract derived from the Baumi situation mushroom.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100014970A KR101208887B1 (en) | 2010-02-19 | 2010-02-19 | Process for Extracting of Styrylpyrone Group Compounds from Phellinus Baumi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100014970A KR101208887B1 (en) | 2010-02-19 | 2010-02-19 | Process for Extracting of Styrylpyrone Group Compounds from Phellinus Baumi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110095486A true KR20110095486A (en) | 2011-08-25 |
| KR101208887B1 KR101208887B1 (en) | 2012-12-05 |
Family
ID=44931102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100014970A KR101208887B1 (en) | 2010-02-19 | 2010-02-19 | Process for Extracting of Styrylpyrone Group Compounds from Phellinus Baumi |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101208887B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102977114A (en) * | 2012-11-20 | 2013-03-20 | 浙江省中医药研究院 | Inoscavin A as a monomeric component in phellinus as well as prepearation method and application thereof |
| KR101426907B1 (en) * | 2012-06-12 | 2014-08-06 | 전북대학교산학협력단 | Composition for preventing or treating hepatic injury comprising davallialactone |
| KR101435638B1 (en) * | 2010-12-24 | 2014-08-28 | 한국생명공학연구원 | A novel hispidin-type compound having enoyl-ACP reductase inhibition and antibacterial activity |
| CN104059080A (en) * | 2014-03-24 | 2014-09-24 | 浙江省中医药研究院 | Preparation method of monomer component Hypholomine B in Phellinus igniarius |
| JP2016020341A (en) * | 2014-06-18 | 2016-02-04 | 有限会社バイオシステムコンサルティング | Anti-obesity agent |
| WO2016159451A1 (en) * | 2015-04-02 | 2016-10-06 | 서울시립대학교 산학협력단 | Composition, for promoting ex vivo material degradation, containing n-, s- and p- and phellinus linteus extract or beta-glucan |
| CN110357843A (en) * | 2019-07-17 | 2019-10-22 | 福建师范大学 | A kind of novel morin and its extracting method and application |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109758451A (en) * | 2018-12-21 | 2019-05-17 | 浙江中医药大学 | Application of the Hypholomine B in preparation prevention or treatment liver injury medicament |
-
2010
- 2010-02-19 KR KR1020100014970A patent/KR101208887B1/en active IP Right Grant
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101435638B1 (en) * | 2010-12-24 | 2014-08-28 | 한국생명공학연구원 | A novel hispidin-type compound having enoyl-ACP reductase inhibition and antibacterial activity |
| KR101426907B1 (en) * | 2012-06-12 | 2014-08-06 | 전북대학교산학협력단 | Composition for preventing or treating hepatic injury comprising davallialactone |
| CN102977114A (en) * | 2012-11-20 | 2013-03-20 | 浙江省中医药研究院 | Inoscavin A as a monomeric component in phellinus as well as prepearation method and application thereof |
| CN102977114B (en) * | 2012-11-20 | 2015-01-14 | 浙江省中医药研究院 | Inoscavin A as a monomeric component in phellinus as well as prepearation method and application thereof |
| CN104059080A (en) * | 2014-03-24 | 2014-09-24 | 浙江省中医药研究院 | Preparation method of monomer component Hypholomine B in Phellinus igniarius |
| JP2016020341A (en) * | 2014-06-18 | 2016-02-04 | 有限会社バイオシステムコンサルティング | Anti-obesity agent |
| WO2016159451A1 (en) * | 2015-04-02 | 2016-10-06 | 서울시립대학교 산학협력단 | Composition, for promoting ex vivo material degradation, containing n-, s- and p- and phellinus linteus extract or beta-glucan |
| CN110357843A (en) * | 2019-07-17 | 2019-10-22 | 福建师范大学 | A kind of novel morin and its extracting method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101208887B1 (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101208887B1 (en) | Process for Extracting of Styrylpyrone Group Compounds from Phellinus Baumi | |
| KR101069959B1 (en) | Liver protection compounds of the cyclohexenone type from Antrodia camphorata | |
| JP2008169194A (en) | Cyclohexanone extract of antrodia camphorata | |
| CA2053820C (en) | Method of inhibiting metabolism of cholesterol | |
| KR20150055876A (en) | Composition for reducing body-fat and weight | |
| KR100883992B1 (en) | Composition containing extracts of Zanthoxylum piperitum DC or compounds isolated therefrom for the prevention and treatment of cardiovascular diseases | |
| KR101577002B1 (en) | Functional food materials and composition | |
| KR101135132B1 (en) | Novel use of panduratin derivatives or extract of Boesenbergia pandurata | |
| KR20170023910A (en) | Pharmaceutical Compositions for Prevention or Treatment of nonalcoholic fatty liver disease Comprising Quercetin-3-O-glucoside | |
| CN113350453B (en) | Composition for raising HDL-C | |
| US20070117864A1 (en) | Composition for preventing and treating hepatoma | |
| Lau et al. | Sclerotium-forming mushrooms as an emerging source of medicinals: current perspectives | |
| JP2016199545A (en) | Sugar and lipid metabolism-improving agents which contain components of citrus sudachi, such as limonene-1,2-diol, as active ingredient | |
| KR101351406B1 (en) | A composition for athero-sclerosis comprising the polyphenol extracts from Phellinus baumii | |
| KR100595459B1 (en) | Composition for inhibiting obesity | |
| KR101708368B1 (en) | Sugar metabolism improving composition, and pharmaceutical preparation containing said composition | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| Tinoco et al. | Effects of a hexane extract from Laurus novocanariensis leaves on the ethanol metabolism of Wistar rats | |
| JP7367959B2 (en) | Brain-derived neurotrophic factor production promoters, nerve growth factor production promoters, oxidative stress inhibitors and their uses | |
| KR20110063129A (en) | A pharmaceutical composition for preventing or treating hypercholesterolemia or cardiovascular disease and a health functional food for preventing or improving hypercholesterolemia or cardiovascular disease, containing an extract of hericium erinaceum hypha cultivated with artemisia capillaries as an effective ingredient | |
| KR100406184B1 (en) | Anti-cholesterol compositions containing acetone extract of sea squirt shell | |
| KR20110093279A (en) | Ampk activators from erythrina abyssinica, and compositions for prevention and treatment of metabolic syndromes through activation of ampk enzyme containing the same as an active ingredients | |
| KR100443265B1 (en) | Novel phenylpyropene A and phenylpyropene B, preparation method thereof and the pharmaceutical composition containing this | |
| KR100408089B1 (en) | Anti-cholesterol compositions containing starfish acetone extract | |
| TWI510244B (en) | Use of extracts of solanum nigrum l. for reducing body fat, body weight and in treating steatohepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| GRNT | Written decision to grant | ||
| X701 | Decision to grant (after re-examination) | ||
| FPAY | Annual fee payment |
Payment date: 20151109 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20161012 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20181113 Year of fee payment: 7 |